Soleus Capital — Full Portfolio
8 tracked investments · listed companies and verified rows first
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystNextech Invest+5 more
Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology.
AI & Machine LearningBiotechDigital HealthHealthtechFramingham, US
Haim Neerman(Co-founder)inTomer Jackman(Co-founder & VP Customer Support and Lab Services)inJeffrey Weisberg(Chief Financial Officer)inYaron Rachmany(Operations, R&D, IT (executive))inChristine Stanley(Chief Genomics and Compliance Officer)inEyal Reinstein(Chief Medical Officer)in
Co-investors20/20 HealthCare Partners LLCBosch VenturesNew Era Capital PartnersOrbiMedPeregrine VenturesPitango+2 more
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+8 more
BiotechHunt Valley, US
Chad Gordon(Manager)Greg Cole(Executive Officer, Director)Jesse Christopher(Executive Officer, Director)
BoardJohn Parker(Director)Jill Kalmann(Director)Matthew B. Swartz(Manager)
Co-investorsTEDCO
Neurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders.
BiotechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Executive Officer)inArnold Kriegstein(Director)
BoardPeter Svennilson(Director)inTim Kutzkey(Director)Ray Kelleher(Director)
Co-investorsBerkeley FrontierIaso VenturesThe Column GroupYsios CapitalAlexandriaFidelity Investments+7 more
Parse.ly is a content analytics and audience intelligence platform offering a real-time dashboard, a content recommendation API, a data pipeline to warehouses, and AI-driven insights.
Data & InfrastructureMarketing TechMedia & Entertainment
Co-investorsHaatchHorizon Technology FinanceJanus Henderson InvestorsSahsen VenturesSARAS CAPITAL
HealthtechIrvine, US
Kenny Chang(Executive Officer)W. Ronald Redmond(Director)Vijay Dhaka(Executive Officer)Philong Pham(Executive Officer, Director)Hongsheng Tong(Executive Officer, Director)
Co-investorsBlackRockEndeavour VisionMVM Life Science PartnersRTW Investments L.P.venBio Global StrategicVivo Capital
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. KruseTimothy Springer(Director)Andrew Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)
Co-investorsEcoR1 CapitalVida VenturesAlly Bridge GroupClarusPolaris Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.